Supply Chain Intelligence

Guardant Health, Inc. Supply Chain

GH supply chain intelligence for Guardant Health, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

GH ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

14Suppliers
24Customers
3Debt Items
20Related Chains

Guardant Health, Inc. Suppliers

TickerNameConfidenceEvidence
CAI Caris Life Sciences, Inc. 72% biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, Inc.; NeoGenomics, Inc.; Exact Sciences…
CAI Caris Life Sciences, Inc. 72% Reciprocal relationship from CAI graph: Reciprocal relationship from GH graph: biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018…
EXAS Exact Sciences Corp 72% Reciprocal relationship from EXAS graph: Reciprocal relationship from GH graph: biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 201…
EXAS Exact Sciences Corp 72% biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, Inc.; NeoGenomics, Inc.; Exact Sciences…
FLGT Fulgent Genetics, Inc. 72% Reciprocal relationship from FLGT graph: ry equipment, supplies, and services for our flow cytometry tests and testing services; on Leica Biosystems for an automated digital scanning solution to scal…
MYGN Myriad Genetics, Inc. 72% Reciprocal relationship from MYGN graph: Reciprocal relationship from GH graph: biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 201…
MYGN Myriad Genetics, Inc. 72% biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, Inc.; NeoGenomics, Inc.; Exact Sciences…
NEO NeoGenomics, Inc. 72% Reciprocal relationship from NEO graph: Reciprocal relationship from GH graph: Reciprocal relationship from NEO graph: Reciprocal relationship from GH graph: Reciprocal relationship from NEO graph: R…
PACB Pacific Biosciences of California, Inc. 72% r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with our tests. In addition, we are aware that certain of our customers a…
PACB Pacific Biosciences of California, Inc. 72% Reciprocal relationship from PACB graph: Reciprocal relationship from GH graph: Reciprocal relationship from PACB graph: Reciprocal relationship from GH graph: r therapy selection, that sell molecula…
TEM Tempus AI, Inc. 72% Reciprocal relationship from TEM graph: Reciprocal relationship from GH graph: Reciprocal relationship from TEM graph: Reciprocal relationship from GH graph: Reciprocal relationship from TEM graph: w…
TMO Thermo Fisher Scientific Inc. 72% Reciprocal relationship from TMO graph: Reciprocal relationship from GH graph: r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that co…
TMO Thermo Fisher Scientific Inc. 72% r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with our tests. In addition, we are aware that certain of our customers a…
VCYT Veracyte, Inc. 72% Reciprocal relationship from VCYT graph: Reciprocal relationship from GH graph: Reciprocal relationship from VCYT graph: y requirements, which may be subject to change, and our failure to comply with…

Guardant Health, Inc. Customers

TickerNameConfidenceEvidence
BIOPHARMACEUTICAL-CUSTOMERS BIOPHARMACEUTICAL-CUSTOMERS 92% Biopharmaceutical customers collaborate with us for analysis of whole blood or plasma samples for multiple applications primarily to support clinical studies, including patient identification, compan…
DOMESTIC-BIOPHARMACEUTICAL-CUSTOMERS DOMESTIC-BIOPHARMACEUTICAL-CUSTOMERS 90% we generate revenue from licensing our digital sequencing technologies to our domestic biopharmaceutical customers and international laboratory partners.
INTERNATIONAL-LABORATORY-PARTNERS INTERNATIONAL-LABORATORY-PARTNERS 90% we generate revenue from licensing our digital sequencing technologies to our domestic biopharmaceutical customers and international laboratory partners.
CAI Caris Life Sciences, Inc. 72% biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, Inc.; NeoGenomics, Inc.; Exact Sciences…
CAI Caris Life Sciences, Inc. 72% Reciprocal relationship from CAI graph: Reciprocal relationship from GH graph: Reciprocal relationship from CAI graph: Reciprocal relationship from GH graph: biopsy space for therapy selection includ…
EXAS Exact Sciences Corp 72% Reciprocal relationship from EXAS graph: Reciprocal relationship from GH graph: biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 201…
EXAS Exact Sciences Corp 72% biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, Inc.; NeoGenomics, Inc.; Exact Sciences…
MYGN Myriad Genetics, Inc. 72% Reciprocal relationship from MYGN graph: Reciprocal relationship from GH graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from GH graph: biopsy space for therapy selection incl…
MYGN Myriad Genetics, Inc. 72% biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, Inc.; NeoGenomics, Inc.; Exact Sciences…
NEO NeoGenomics, Inc. 72% Reciprocal relationship from NEO graph: rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities in this market within the laboratory tes…
PACB Pacific Biosciences of California, Inc. 72% r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with our tests. In addition, we are aware that certain of our customers a…
PACB Pacific Biosciences of California, Inc. 72% Reciprocal relationship from PACB graph: Reciprocal relationship from GH graph: Reciprocal relationship from PACB graph: Reciprocal relationship from GH graph: Reciprocal relationship from PACB graph…
TEM Tempus AI, Inc. 72% Reciprocal relationship from TEM graph: who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are running, or as a companion diagnostic to t…
TMO Thermo Fisher Scientific Inc. 72% r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with our tests. In addition, we are aware that certain of our customers a…
TMO Thermo Fisher Scientific Inc. 72% Reciprocal relationship from TMO graph: Reciprocal relationship from GH graph: r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that co…
VCYT Veracyte, Inc. 72% Reciprocal relationship from VCYT graph: Reciprocal relationship from GH graph: Reciprocal relationship from VCYT graph: Reciprocal relationship from GH graph: Reciprocal relationship from VCYT graph…
ADICON-HOLDINGS-LIMITED ADICON-HOLDINGS-LIMITED 62% lated to the amount that payers reimburse us for any of our tests, we estimate the amount of revenue to be recognized at the time a test is provided and record revenue adjustments if and when the cas…
BIO-REFERENCE-LABORATORIES-INC-LABORATORY-CORPOR BIO-REFERENCE-LABORATORIES-INC-LABORATORY-CORPOR 62% ening testing space include GRAIL, Inc., Exact Sciences Corp., Freenome Holdings, Inc., and Delfi Diagnostics. Competitors within the broader genomics profiling space based on tissue include laborato…
CALIFORNIA-INC-ULTIMA-GENOMICS-INC-OXFORD-NANOPO CALIFORNIA-INC-ULTIMA-GENOMICS-INC-OXFORD-NANOPO 62% performing certain services. If we are unable to compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our tests, which could preven…
GRAIL-INC-EXACT-SCIENCES-CORP-FREENOME-HOLDINGS- GRAIL-INC-EXACT-SCIENCES-CORP-FREENOME-HOLDINGS- 62% ening testing space include GRAIL, Inc., Exact Sciences Corp., Freenome Holdings, Inc., and Delfi Diagnostics. Competitors within the broader genomics profiling space based on tissue include laborato…
ILLUMINA-INC-THERMO-FISHER-SCIENTIFIC-INC ILLUMINA-INC-THERMO-FISHER-SCIENTIFIC-INC 62% performing certain services. If we are unable to compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our tests, which could preven…
MYRIAD-GENETICS-INC-CARIS-LIFE-SCIENCE-FOUNDATIO MYRIAD-GENETICS-INC-CARIS-LIFE-SCIENCE-FOUNDATIO 62% tory Corporation of America. In addition, Natera, Inc., Tempus AI, Inc., Exact Sciences Corp., Myriad Genetics, Inc., Caris Life Science, Foundation Medicine, Inc. and Quest Diagnostics, Inc., among …
NATERA-INC-TEMPUS-AI-INC-EXACT-SCIENCES-CORP NATERA-INC-TEMPUS-AI-INC-EXACT-SCIENCES-CORP 62% tory Corporation of America. In addition, Natera, Inc., Tempus AI, Inc., Exact Sciences Corp., Myriad Genetics, Inc., Caris Life Science, Foundation Medicine, Inc. and Quest Diagnostics, Inc., among …
QUEST-DIAGNOSTICS-INC QUEST-DIAGNOSTICS-INC 62% ening testing space include GRAIL, Inc., Exact Sciences Corp., Freenome Holdings, Inc., and Delfi Diagnostics. Competitors within the broader genomics profiling space based on tissue include laborato…

Guardant Health, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
GH-DEBT Debt stack $1.7B 90% Market cache reports total debt of $1.7B.
GH-DEBT-9777 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.
GH-DEBT-9776 Warrants outstanding: 495775 90% xbrl warrant detail from xbrl 2020-12-31.

Guardant Health, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Guardant Health, Inc..

Guardant Health, Inc. Ownership

HolderNameConfidenceEvidence
GH-OWNER-BLACKROCK-INC BlackRock, Inc. 90% 13F overlay lists BlackRock, Inc. as top holder; 488 tracked holders.

Guardant Health, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ABT Abbott Laboratories 100.00 2
BNBX BNB Plus Corp. 100.00 2
CAI Caris Life Sciences, Inc. 100.00 2 ['customer', 'supplier']
BTAI BioXcel Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
RXRX Recursion Pharmaceuticals, Inc. 100.00 2
ELVN Enliven Therapeutics, Inc. 100.00 2
DGX Quest Diagnostics Incorporated 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
PSNL Personalis, Inc. 100.00 1 ['spend']
CAPR Capricor Therapeutics, Inc. 100.00 2
BNTC Benitec Biopharma Inc. 100.00 2
CALC CalciMedica, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
BNR Burning Rock Biotech Limited 100.00 2
GRAL GRAIL, Inc. 100.00 1 ['spend']
SDGR Schrödinger, Inc. 100.00 2
TECX Tectonic Therapeutic, Inc. 100.00 2
CABA Cabaletta Bio, Inc. 100.00 2
ATYR aTyr Pharma, Inc. 100.00 2
View GH supply chain intel →

Explore the full interactive supply chain map for Guardant Health, Inc..

Open GH supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map